| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | VCNX | Common Stock | 22,116 | 02 Nov 2023 | Direct | ||||||
| holding | VCNX | Common Stock | 14,214 | 02 Nov 2023 | By Jeremy C. Zauderer Trust | F1 | |||||
| holding | VCNX | Common Stock | 14,145 | 02 Nov 2023 | By Jordan M. Zauderer Trust | F1 | |||||
| holding | VCNX | Common Stock | 979,599 | 02 Nov 2023 | By Vaccinex (Rochester), L.L.C. | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VCNX | Warrant (Right to Buy) | Award | $17,094 | +136,752 | $0.125 | 136,752 | 02 Nov 2023 | Common Stock | 136,752 | $2.34 | By Vaccinex (Rochester), L.L.C. | F2 | |
| holding | VCNX | Warrant (Right to Buy) | 500,000 | 02 Nov 2023 | Common Stock | 500,000 | $1 | By Vaccinex (Rochester), L.L.C. | F2 | |||||
| holding | VCNX | Stock Option (Right to Buy) | 172 | 02 Nov 2023 | Common Stock | 172 | $223.5 | Direct | F3 | |||||
| holding | VCNX | Stock Option (Right to Buy) | 172 | 02 Nov 2023 | Common Stock | 172 | $223.5 | Direct | F3 | |||||
| holding | VCNX | Stock Option (Right to Buy) | 221 | 02 Nov 2023 | Common Stock | 221 | $106.5 | Direct | F3 | |||||
| holding | VCNX | Stock Option (Right to Buy) | 1,333 | 02 Nov 2023 | Common Stock | 1,333 | $64.35 | Direct | F3 | |||||
| holding | VCNX | Stock Option (Right to Buy) | 1,893 | 02 Nov 2023 | Common Stock | 1,893 | $100.2 | Direct | F4 | |||||
| holding | VCNX | Stock Option (Right to Buy) | 933 | 02 Nov 2023 | Common Stock | 933 | $43.95 | Direct | F5 | |||||
| holding | VCNX | Stock Option (Right to Buy) | 1,866 | 02 Nov 2023 | Common Stock | 1,866 | $19.35 | Direct | F6 | |||||
| holding | VCNX | Stock Option (Right to Buy) | 3,733 | 02 Nov 2023 | Common Stock | 3,733 | $6.59 | Direct | F7 |
| Id | Content |
|---|---|
| F1 | Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| F2 | Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| F3 | Exercisable in full as of the date of this report. |
| F4 | This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date. |
| F5 | This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date. |
| F6 | This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date. |
| F7 | This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date. |